Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02032758 · ClinicalTrials.gov registry record · Phase 4

Study of Arm and Putter Movement in Golfers With Golfer's Cramp

A Phase 4 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
38
Enrollment target

NCT02032758: Completed Phase 4 study, sponsored by Mayo Clinic.

NCT02032758 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02032758, a Phase 4 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
38 participants
Enrollment target

Study Summary

The investigators will investigate golfers with visual evidence of an involuntary movement while putting before and after treatment with a low dose of propranolol.

Primary Outcome

"Dynamic change of rotation at impact" is the velocity of rotation of the putter from the start of the forward swing until the time of impact with the golf ball.

Interventions

  • DRUG Propranolol
  • DEVICE Opal Device
  • PROCEDURE Science and Motion PuttLab (SAM)
  • DEVICE Surface Electromyography EMG

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2014-01
Est. Completion 2015-01
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT02032758 record still lists

NCT02032758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 4 interventions - of which Propranolol is the first listed.

NCT02032758 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02032758 about?

NCT02032758 is a clinical study titled "Study of Arm and Putter Movement in Golfers With Golfer's Cramp". The investigators will investigate golfers with visual evidence of an involuntary movement while putting before and after treatment with a low dose of propranolol.

What is the current status of trial NCT02032758?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2014-01. Estimated completion is 2015-01.

What interventions are being tested in trial NCT02032758?

The interventions under investigation include: Propranolol (DRUG), Opal Device (DEVICE), Science and Motion PuttLab (SAM) (PROCEDURE), Surface Electromyography EMG (DEVICE).

Who is sponsoring clinical trial NCT02032758?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02032758's enrollment target sits among peer trials

38 1476th of 2000 higher than 519 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02032758, the US trial registry maintained by the National Library of Medicine. NCT02032758 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.